Ruminant Diseases and Immunology Research Unit Site Logo
ARS Home About Us Helptop nav spacerContact Us En Espanoltop nav spacer
Printable VersionPrintable Version     E-mail this pageE-mail this page
Agricultural Research Service United States Department of Agriculture
Search
  Advanced Search
 
Programs and Projects
Subjects of Investigation
 

Research Project: IDENTIFICATION OF FACTORS ASSOCIATED WITH IMMUNE SUPPRESSION AND MASTITIS

Location: Ruminant Diseases and Immunology Research Unit

Title: Activation of immune cells in bovine mammary gland secretions by zymosan treated bovine serum

Authors
item Kimura, Kayoko
item Goff, Jesse
item Schmerr, Mary
item Stabel, Judith
item Inumaru, Shigeki - NATL INST ANIM HLTH-JPN
item Yokomizo, Yuuichi - NATL INST ANIM HLTH-JPN

Submitted to: Journal of Dairy Science
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: January 18, 2008
Publication Date: April 20, 2008
Citation: Kimura, K., Goff, J.P., Schmerr, M.J., Stabel, J.R., Inumaru, S., Yokomizo, Y. 2008. Activation of immune cells in bovine mammary gland secretions by zymosan-treated bovine serum. Journal of Dairy Science. 91(5):1852-1864.

Interpretive Summary: The greatest risks of intramammary infection occur at the end of lactation and at the initiation of the next lactation. If we can activate neutrophils and lymphocytes during these periods of risk we may be able to reduce new intramammary infections during the dry period as well as at the initiation of the next lactation. Bovine serum, pre-treated with a yeast cell wall preparation (zymosan), was infused into one half of the mammary gland of 8 cows shortly after dry off. This treatment succeeded in activating both neutrophils and lymphocytes as evidenced by the expression of IFN-g and IL-8 in the cells obtained from the zymosan serum–infused quarters vs. saline infused quarters. Expression of these cytokines increased within 48 hours of infusion and the higher level of activation of the immune cells lasted through the first two weeks of the next lactation.

Technical Abstract: Mastitis, caused by bacterial infection of the mammary gland, is a major disease of dairy cattle. The greatest risks of intramammary infection occur at the end of lactation and at the initiation of the next lactation when the cow calves. Treating serum with zymosan (yeast cell wall preparation) causes complement to cleave, allowing this serum to serve as a source of C5a, a potent chemo-attractant and activator of the immune system. Our hypothesis was that intramammary infusion of zymosan-treated serum (ZTS) would recruit neutrophils and generate prolonged activity in lymphocytes within the mammary gland. Ultimately this could help prevent bacterial infections in cows at dry off and at the initiation of lactation. Two ipsilateral quarters of the mammary gland of each cow were infused with ZTS (12.5 mL/quarter) and two quarters with saline in 8 cows shortly after lactation ended. Mammary secretions were collected periodically throughout the dry period and the first two weeks of the next lactation. Activation status of lymphocytes and neutrophils in those secretions was assessed based on the intracellular presence or absence of IFN-gamma and IL-8 as determined by flow cytometry. ZTS infusion greatly increased neutrophil numbers in mammary secretions for the first week only. The percentage of IFN-gamma positive lymphocytes and neutrophils and the percentage of IL-8 positive neutrophils exhibited a sustained increase in secretions from ZTS treated quarters through the first two weeks of lactation (P < 0.1). ZTS can stimulate neutrophil and lymphocyte mediated immune defense mechanisms in the mammary gland, which may provide a useful means of preventing new intramammary infections during the dry period as well as at the initiation of lactation.

   

 
Project Team
Lippolis, John
Reinhardt, Timothy - Tim
 
Publications
   Publications
 
Related National Programs
  Animal Health (103)
 
 
Last Modified: 05/24/2013
ARS Home | USDA.gov | Site Map | Policies and Links 
FOIA | Accessibility Statement | Privacy Policy | Nondiscrimination Statement | Information Quality | USA.gov | White House